In the absence of a GPX4 inhibitor with good in vivo bioavailability, we turned to sulfasalazine, a system xc− inhibitor, to establish the feasibility for targeting lipid peroxide metabolism in our NCI-HCC PDX model. This evidence concerns the gene GPX4 and hepatocellular carcinoma.